Dallas, TX: ReportsandReports announce F. Hoffmann-La Roche Ltd.: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/8200-f-hoffmann-la-roche-ltd-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Roche’s performance against key rivals in the prescription pharmaceutical sector
• Assess the impact of Roche’s full corporate acquisition of US biotech partner Genentech which completed earlier this year
• Learn how the company’s three key monoclonal antibodies: MabThera/Rituxan, Herceptin and Avastin, will account for over 80% of sales growth to 2015
Table Of Contents
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
Roche: PharmaVitae forecasts at a glance
Strategic insight
A defining moment: Roche’s merger with Genentech, a precursor to full acquisition
Sales source analysis 2003-15
Reliance on the big three
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Table of Contents
Table of figures
Chapter 3 Quarterly news update
Latest quarterly sales
Latest comment
Q1 2010
Roche: novel Herceptin formulation promises greater convenience
Q4 2009
Roche: NICE’s hesitation is a setback for RoActemra
Genentech/Roche: UK’s NICE remains negative over Avastin for colorectal cancer
Genentech/Roche: another boost for blockbuster Avastin
Roche: RoActemra launches in UK despite NICE’s unfavorable initial opinion
Q3 2009
Roche/Genentech: encouraging data point to Avastin potential in melanoma
Genentech/Roche/Chugai: Avastin gets FDA go-ahead for kidney cancer
Q2 2009
Genentech/Roche: Avastin adds fifth indication to label
Q1 2009
Genentech/Roche/Chugai: Herceptin shows activity in gastric cancer
Genentech/Roche/Biogen Idec: Rituxan receives EU boost
Latest prescription pharma product news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q2 2009
Latest corporate news
Q4 2009
Q3 2009
Q1 2009
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
Pharmaceuticals division
Genentech
Chugai
Diagnostics division
Divestments
M&A history
M&A strategy
Genentech
Overview
‘Locking in’ mAb expertise
Product licensing agreement
US sales consolidation
Move to acquire remaining shares in Genentech
Renewed bid by Roche accepted by Genentech
Chugai
Japanese position strengthened
Non-integrative merger
Boost to Chugai pipeline…
and a boost to Roche’s pipeline
Large-scale M&A
Recent small-scale M&A
454 Life Sciences
Therapeutic Human Polyclonals (THP)
BioVeris
NimbleGen
Alnylam
Mirus Bio Corporation
ARIUS
Memory Pharmaceuticals
Innovatis AG
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Product analysis, 2003-09
Product analysis, 2009-15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009-15
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
Operating costs and profit analysis
Operating costs and profit analysis, 2003-09
Operating cost ratio and profit margin analysis, 2003-09
Operating cost ratio and profit margin analysis, 2009-15
Operating costs and profit analysis, 2009-15
Chapter 7 Key products
Overview
Avastin
Summary
Sales forecast
Herceptin
Summary
Sales forecast
MabThera
Summary
Sales forecast
Actemra
Delay to launch in the US
Large Phase III program and excellent clinical efficacy enable Actemra to compete with Rituxan and Orencia, but also at first-line
Product positioning
Future performance
Summary
Sales forecast
Tarceva
Summary
Sales forecast
Mircera
Summary
Sales forecast
Tamiflu
Summary
Sales forecast
CellCept
Summary
Sales forecast
NeoRecormon
Summary
Sales forecast
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaVitae Market
http://www.reportsandreports.com/reports/8200-f-hoffmann-la-roche-ltd-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
F. Hoffmann-La Roche Ltd-Deals & Alliances Report
http://www.reportsandreports.com/reports/31735-f-hoffmann-la-roche-ltd-deals-alliances-report.html
F. Hoffmann-La Roche Ltd-Detailed Product Pipeline
http://www.reportsandreports.com/reports/29621-f-hoffmann-la-roche-ltd-detailed-product-pipeline.html
F. Hoffmann-La Roche Ltd-Company Report
http://www.reportsandreports.com/reports/5226-f-hoffmann-la-roche-ltd-company-report.html
F. Hoffmann-La Roche Ltd – SWOT Analysis
http://www.reportsandreports.com/reports/1962-f-hoffmann-la-roche-ltd-swot-analysis.html
F. Hoffmann-La Roche Ltd. Market Share Analysis
http://www.reportsandreports.com/reports/15583-f-hoffmann-la-roche-ltd-market-share-analysis.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
